ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Research Article
Revised

Burden of drug-resistant pulmonary tuberculosis in Pakistani children: A cross-sectional study

[version 2; peer review: 1 approved with reservations, 1 not approved]
PUBLISHED 26 Apr 2019
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the World TB Day collection.

Abstract

Introduction: The incidence of drug-resistant tuberculosis (TB) is rapidly increasing worldwide. Children in high TB burden countries are rapidly being reported to be affected by Mycobacterium tuberculosis resistant to isoniazid and rifampicin. The aim of this study is to evaluate the pattern of drug sensitivity among children suffering with TB.
Methods: Known cases of pulmonary TB, with sputum smear positive for acid-fast bacilli after two months of compliance to 1st line anti-tuberculous therapy were included after gaining informed consent. Specimens used for drug sensitivity testing were either sputum or bronchoalveolar lavage. Patient age, gender, history of TB contact, and duration of treatment were also recorded. Data was entered and analyzed using SPSS v.22.
Results: Fifty children, 32 male (64%) and 18 female (36%) were included in the study. Their mean age was 12.84 ± 2.54 years. History of household TB contact was positive in 29 (58%) children. Among 1st line anti-tuberculous therapy, rifampicin resistance was highest at 33/50 (66%), and resistance to streptomycin and ethambutol were the lowest (6/50; 12%). There were 18 (36%) children with multidrug-resistant tuberculosis (MDR-TB). A positive history of household TB contact (either resistant or non-resistant) was seen to have a statistically significant impact on incidence of MDR-TB (p value=0.03)
Conclusion: Pediatric drug-resistant TB is a rising concern. Awareness programs on national and international levels are needed to educate general population regarding the importance of preventing TB household contact, especially amongst children. With the selected method used to identify mainly older children with drug resistance, the yield for drug-resistant TB was found to be high.

Keywords

pediatric tuberculosis, multi-drug resistant tuberculosis, isoniazid, rifampicin, household T contact, Pakistan

Revised Amendments from Version 1

In the version 2 of this manuscript, significant changes have been made in the abstract, introduction, results and methodology sections according to the valuable comments from reviewer. Some phrases are changed for a better understanding of the readers and to maintain consistency. Conclusions of the study are rephrased to be more according to the results of this work, rather than what was concluded previously. Three references have been added to justify one of the findings made about rifampin. An interesting finding has been added about Pre-XDR. Limitations section of discussion has been updated. Some minor changes have also been made.

See the authors' detailed response to the review by H. Simon Schaaf

Introduction

Globally, there are approximately 67 million children suffering from Mycobacterium tuberculosis (MTB) infection. It is estimated that 5 million children are infected with Isoniazid (INH) mono-resistant MTB strains and 2 million with multidrug-resistant (MDR) strains. In 2014 alone, an estimated 850,000 children developed pulmonary tuberculosis with 25,000 multidrug-resistant cases1. The statistics surged drastically, and in 2017 1 million new cases of paediatric TB were reported2. Adding to the current poor trajectory there have also been reports of extensive drug resistance (XDR) in paediatric pulmonary tuberculosis, with almost 100,000 children found infected with XDR strains1.

In TB patients, drug resistance results from spontaneous genetic mutations in the MTB genome. The risk of genetic mutation increases with increasing bacterial load, explaining why resistance is more commonly seen in adult cavitary TB, which has large bacilli load. In children the more common reasons of drug resistance are transmission of a resistant bacillus and previous treatment with anti-tuberculous therapy (ATT). Other factors that predispose to drug-resistant TB include inappropriate drug regimens, monotherapy, and drug non-adherence3.

Pakistan is among the top 20 TB-endemic countries, which share 84% of global TB burden and 87% of multidrug-resistant tuberculosis (MDR-TB) burden, according to the World Health Organization (WHO)2. Though, there have been various studies highlighting the incidence of MDR-TB in Pakistani adults4, and some studies also included children; we couldn’t find any study from Pakistan that discussed the incidence of paediatric MDR-TB in particular. The aim of this study is to assess the pattern of sensitivity to 1st line and 2nd line ATT among Pakistani children (≤18 years).

Methods

A prospective, cross-sectional study was conducted from 1st July 2018 to 31st Dec 2018 in the Department of Paediatrics, Civil Hospital, Jamshoro. Known cases of pulmonary tuberculosis being followed up at the outpatient TB clinic were recruited. The inclusion criteria included children <18 years with a working diagnosis of pulmonary TB who had been taking 1st line ATT for two months but still had sputum smears (or sputum culture) positive for MTB. For children less than five years old, informed consent was taken from their parents/guardians. For children of age five years or above, informed consent from the parents/guardians and assent from the children was taken. Children who had become negative for MTB on sputum smear or culture with 1st line ATT, indicating response to these drugs, were not included. Children who were sputum positive but also non-compliant to their medications (those not taking/not given their medications regularly as assessed from their TB dosage card) were also excluded. Follow up patients in the TB clinic whose parents/guardians did not consent or children older than 5 who did not assent to participate were also excluded.

For culture and sensitivity, either sputum sample was utilized or bronchoalveolar lavage specimen (in cases of no sputum production). The samples were not specifically taken for this research, but were a part of their standard management, hence, no additional burden was placed on the participants of the study. Mycobacterium was isolated from the specimens by using Lowenstein-Jensen medium and Mycobacterium Growth Indicator Tube (MGIT) medium (Becton Dickinson, Franklin Lakes, NJ, USA). BACTEC NAP test (Becton Dickinson) was then performed on the isolated mycobacterium to differentiate MTB from other mycobacteria. Drug sensitivity testing was then done using an agar proportion method on enriched Middle brook 7H10 medium (BBL Microbiology Systems, Cockeysville, MD, USA) following the standard laboratory protocols of the Civil Hospital, Jamshoro. Concentrations used for every drug was: isoniazid (INH) 0.2μg/ml, rifampicin (RIF) 1μg/ml, ethambutol (EMB) 5μg/ml, and streptomycin (SM) 2μg/ml and 10μg/ml. For pyrazinamide (PZA) sensitivity, BACTEC 7H12 medium was used with pH 6.0, at 100μg/ml (BACTEC PZA test medium, Becton Dickinson). Strains which were resistant to INH and RIF were termed as MDR strains. MDR-TB strains were then tested for sensitivity to 2nd anti-tuberculosis agents: capreomycin 10μg/ml, ofloxacin 2μg/ml, ethionamide 5μg/ml, and kanamycin 6 μg/ml.

A brief questionnaire (See Extended data5) was generated which included patient demographics such as age, gender, history of TB contact, and duration of treatment. Data was entered and analyzed using SPSS Version 22.0. Armonk, NY: IBM Corp. Mean ± standard deviation (SD) was calculated for continuous variables such as age and duration of treatment. Frequency and percentages were calculated for all other variables including drug sensitivity.

Results

The study was completed by 50 children. There were 32 male (64%) and 18 female (36%) children in the study. Their mean age was 12.84 ± 2.54 years with the youngest child being 7 and the oldest 18. The demographic profile of these patients is shown in Table 1 (data at patient level is available as Underlying data5).

Table 1. Demographics profile of the patients.

Patient characteristicsFrequency n (%)
Age in years (mean ± SD)12.84 ± 2.54
Duration of treatment in
months (mean ± SD)
3.34 ± 2.27
Gender
              Male
           Female

32 (64%)
18 (36%)
History of TB contact
            Yes
            No

29 (58%)
21 (42%)

TB – Tuberculosis

The sensitivity pattern of 1st line ATT is shown in Table 2. There were 32 (64%) children with combined sensitivity to INH and RIF and 18 (36%) children were multidrug-resistant i.e., combined resistance to INH and RIF. Other than MDR cases, and among the first line drugs used alone, RIF showed the highest isolated resistance (n=33; 66%), while two of those MDR cases were also resistant to Ofloxacin (PreXDR-TB).

Table 2. Sensitivity pattern to first line anti-tuberculosis agent on sputum samples.

DRUGSENSITIVITY n (%)RESISTANCE n (%)
STREPTOMYCIN44 (88%)6 (12%)
ISONIAZID20 (40%)30 (60%)
RIFAMPICIN17 (34%)33 (66%)
ISONIAZID +
RIFAMPICIN (MDR)
32 (64%)18 (36%)
PYRAZINAMIDE25 (50%)25 (50%)
ETHAMBUTOL44 (88%)6 (12%)

MDR- multidrug-resistant

Of the 18 MDR cases, 10 (55.6%) were boys and 8 (44.4%) were girls. Their mean age was 14.01 ± 1.50 years with the youngest of aged 12 and oldest aged 15.

The sensitivity pattern of second-line line ATT is shown in Table 3.

Table 3. Sensitivity pattern to second line anti-tuberculosis agent on sputum samples.

DRUGSENSITIVITY n (%)RESISTANCE n (%)
KANAMYCIN50 (100%)0 (0%)
CAPREOMYCIN50 (100%)0 (0%)
ETHIONAMIDE47 (94%)3 (6%)
OFLOXACIN38 (76%)12 (24%)

A positive history of household TB contact (either resistant or non-resistant) was seen to have a statistically significant impact on incidence of MDR-TB as seen in Table 4.

Table 4. Impact of household tuberculosis (TB) contact history on incidence of multidrug-resistant (MDR)-TB.

Household TB
contact history
Incidence of
MDR-TB n (%)
No incidence of
MDR-TBn (%)
P value
Positive (n=29)14 (48.3%)15 (51.7%)0.03
Negative (n=21)4 (19%)17 (81%)

Discussion

The incidence of drug-resistant TB among children is a global health concern. Public health specialists must pay keen attention to this issue in order to prevent unnecessary mortalities. Pakistan is already a high TB burden country. Poor detection, diagnosis, and management of TB, along with child household contacts of MDR-TB cases not being screened and managed appropriately, has markedly contributed to the rising incidence of MDR-TB among both adults and children in Pakistan6. This study reported 66% of children to be resistant to RIF, 36% to be MDR, and although no case of extensive drug resistance was seen, 24% of children tested positive for fluoroquinolone resistance. It can be extracted from the provided data that out of the total 33 cases of rifampin resistant strains, 15 were mono-resistant to rifampin. Including Pakistan, in other countries the incidence of rifampin resistance is rising and our results are parallel79.

Comparatively, in a Pakistani study conducted in 2010–14, of all the MDR-TB cases in the study, only 1.6% were aged 0–144. In another survey from 2013–14, household contacts of 209 diagnosed cases of MDR-TB were screened. It was seen that 378 of 1463 contacts (26%) were children aged 0–15. Of these, 11 children were symptomatic for TB, were tested, and 4 cases of TB were diagnosed from these children, all of which were MDR10. This study highly reinforces the impact of household TB contact on the development of MDR-TB in children, which has also been highlighted in our study. In another study, with 62% individuals resistant to all first-line agents, ofloxacin resistance was among 52.7%; which is relatively low in the current study (24%)11.

This study highlights the prevailing situation of anti-tuberculosis resistance in Pakistani children and their predisposing factors. It emphasizes the need to protect the children from TB infected persons. This study has its limitations too. It was based in one institute only which is in the rural part of Pakistan. The actual aim of this study was to identify drug resistance to ATT in children of all ages, however, most study participants are adolescents. Hence, this study doesn't represent all TB population and the data cannot be compared to data of more general drug resistance surveys. Multi-center studies all across Pakistan must be conducted to completely understand the current status of anti-tuberculosis drugs resistance in Pakistan among both children as well as adults. Studies should also be conducted to evaluate disease outcome in these patients.

Conclusion

Drug-resistant TB, especially in the pediatric population, is a public health concern. Awareness programs on national and international levels are needed to educate the masses regarding importance of preventing TB household contact especially among the children. With the selected method used to identify mainly older children with drug resistance, the yield for drug-resistant TB was found to be high. Long term studies should be conducted to study the prognosis of children with MDR-TB and deduce strategies to prevent drug resistance.

Ethical approval and consent to participate

The study was assessed and approved by the Institutional Review Board of Civil Hospital, Jamshoro (IERB: 18-679) with informed consent taken from all participants.

Data availability

Underlying data

Figshare: Burden of drug-resistant pulmonary tuberculosis in Pakistani children. https://doi.org/10.6084/m9.figshare.7823741.v45

This project contains the following underlying data:

  • PTB.sav (Antibiotic sensitivity analysis data)

  • Data Dictionary.spv (Data dictionary for underlying data)

Extended data

Figshare: Burden of drug-resistant pulmonary tuberculosis in Pakistani children. https://doi.org/10.6084/m9.figshare.7823741.v45

This project contains the following extended data:

  • Questionnaire.docx (Study questionnaire)

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 27 Mar 2019
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Laghari GS, Hussain Z, Khemani L et al. Burden of drug-resistant pulmonary tuberculosis in Pakistani children: A cross-sectional study [version 2; peer review: 1 approved with reservations, 1 not approved] F1000Research 2019, 8:344 (https://doi.org/10.12688/f1000research.18507.2)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 2
VERSION 2
PUBLISHED 26 Apr 2019
Revised
Views
4
Cite
Reviewer Report 23 Jul 2019
Nazia Jamil, Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan 
Approved with Reservations
VIEWS 4
General Comments
  1. Paediatric TB includes children between ages 0-14, not above them. You must clear this point.
     
  2. In the previous version the reviewer asked about from how many children
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Jamil N. Reviewer Report For: Burden of drug-resistant pulmonary tuberculosis in Pakistani children: A cross-sectional study [version 2; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2019, 8:344 (https://doi.org/10.5256/f1000research.20854.r50668)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
22
Cite
Reviewer Report 07 May 2019
H. Simon Schaaf, Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa 
Not Approved
VIEWS 22
The revised manuscript shows improvement from the original version; however, the reviewer has some additional major comments which need correction.

Major comments:
Results:
  • Page 3, 2nd column, last paragraph running
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Schaaf HS. Reviewer Report For: Burden of drug-resistant pulmonary tuberculosis in Pakistani children: A cross-sectional study [version 2; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2019, 8:344 (https://doi.org/10.5256/f1000research.20854.r47707)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 1
VERSION 1
PUBLISHED 27 Mar 2019
Views
7
Cite
Reviewer Report 11 Apr 2019
H. Simon Schaaf, Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa 
Approved with Reservations
VIEWS 7
Data on the burden or incidence of drug-resistant tuberculosis (DR-TB) in children is sparse, as bacteriological confirmation of tuberculosis in children is challenging. This study did not set out to determine the incidence of DR-TB in Pakistani children in their ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Schaaf HS. Reviewer Report For: Burden of drug-resistant pulmonary tuberculosis in Pakistani children: A cross-sectional study [version 2; peer review: 1 approved with reservations, 1 not approved]. F1000Research 2019, 8:344 (https://doi.org/10.5256/f1000research.20251.r46354)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 11 Apr 2019
    Uzair Yaqoob, Jinnah Postgraduate Medical Centre, Karachi, Pakistan
    11 Apr 2019
    Author Response
    Thank you so much for this great and comprehensive review, we will surely consider all comments and upload the updated versions with editing done as much as we can.
    Competing Interests: No competing interests were disclosed.
  • Author Response 23 Apr 2019
    Uzair Yaqoob, Jinnah Postgraduate Medical Centre, Karachi, Pakistan
    23 Apr 2019
    Author Response
    Response to comments is following, a newer version has been uploaded. the reviewer will soon see the newer version.

    Major comments
    1. Done
    2. Done
    3. Done
    4. Rightly said,
    ... Continue reading
COMMENTS ON THIS REPORT
  • Author Response 11 Apr 2019
    Uzair Yaqoob, Jinnah Postgraduate Medical Centre, Karachi, Pakistan
    11 Apr 2019
    Author Response
    Thank you so much for this great and comprehensive review, we will surely consider all comments and upload the updated versions with editing done as much as we can.
    Competing Interests: No competing interests were disclosed.
  • Author Response 23 Apr 2019
    Uzair Yaqoob, Jinnah Postgraduate Medical Centre, Karachi, Pakistan
    23 Apr 2019
    Author Response
    Response to comments is following, a newer version has been uploaded. the reviewer will soon see the newer version.

    Major comments
    1. Done
    2. Done
    3. Done
    4. Rightly said,
    ... Continue reading

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 27 Mar 2019
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.